Full-Time

Manager – Financial Planning & Analysis

Fp&a

Posted on 1/31/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$136k - $165kAnnually

Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Coupa
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in finance, Accounting, or related field
  • CPA or MBA preferred.
  • 4+ years’ experience in similar role in biotechnology industry
  • Highly proficient in Excel and PowerPoint
  • Demonstrated experience utilizing financial systems and other business intelligence tools; Sage Intaact, Adaptive Insights (including OfficeConnect), and Coupa experience a plus.
  • Experience working effectively in a fast-paced environment with minimal direction.
  • Strong work ethic and ability to adjust workload based on changing priorities.
  • Highest standards of accuracy, precision, and attention to detail; highly organized
  • Ability to think creatively, highly driven, and initiative-taking.
Responsibilities
  • Supporting and serving as the financial G&A business partner for our Commercial, Legal, Finance, HR, Facilities, and IT teams
  • Work cross-functionally with R&D Business partners including Biology and Chemistry
  • Prepare monthly variance analysis of actuals to forecast and budget, explain, and investigate any major discrepancies, and understand key business drivers.
  • Play key role in preparing monthly internal financial management reporting package.
  • Work closely with accounting to forecast and track activities for internal functions including tracking headcount and CAPEX purchases.
  • Maintain reporting tools to report and communicate company’s financial metrics, including the team’s financial planning software (Adaptive Insights)
  • Support annual budget and forecasting process, including budget and forecast template preparation, perform additional analyses that support budget and forecasting needs and prepare PowerPoint slides as needed.
  • Review purchase requests against budgeted amount and account coding
  • Help drive process improvements and efficiencies in areas of financial planning, financial analysis, and production of reporting packages.
  • Support monthly accounting close process.
  • Ad hoc reporting and analysis, as needed.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Strong investor confidence shown by recent upsized public offering.
  • Growing interest in targeted therapies aligns with their focus on RAS mutations.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M public stock offering could result in shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competitive risk.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE